Pemetrexed

(Alimta®)

Alimta®

Drug updated on 9/14/2023

Dosage FormInjection (intravenous; 100 mg or 500 mg)
Drug ClassFolate analog metabolic inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
  • Indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.
  • Indicated as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
  • Indicated as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.